Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × Goserelin × Clear all

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 48 Breast Neoplasms 36 Neoplasms 4 Salivary Gland Neoplasms 3 Prostate Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Recurrence 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Inflammatory Breast Neoplasms 1 Hormone-sensitive Metastatic Breast Cancer 1 Hormone Sensitive Prostate Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Fallopian Tube Neoplasms 1 Castrate Sensitive Prostate Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 7 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 Vinorelbine 2 Trastuzumab 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Moxifloxacin 1 Letrozole 1 Goserelin 1 Everolimus 1 Dasatinib 1 Cyclophosphamide 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04862143 2024-06-20

TELEPIK

Novartis

Phase 2 Terminated

2 enrolled 10 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡